These data suggest the contribution of increases in RELMβ in the gut and Kupffer cells to NASH development, raising the possibility of RELMβ being a novel therapeutic target for NASH. The gene discussed is RETNLB; the disease is metabolic dysfunction-associated steatohepatitis.